VP, Medicine Development Leader- Cancer Vaccines, Oncology Research Unit

For candidates seeking to be located at our Stevenage site, this role will temporarily be based ever, the Company plans to relocate its offices to Cambridge, UK. The location of this role will therefore subsequently change to Cambridge, UK in accordance with timelines to be set by the Company. The relocation is currently proposed to take effect by early 2029.

• Act as GSK's single point of accountability for the global development of a cancer vaccine asset from C2P2 (or the oncology equivalent stage) through approval and launch across all indications in major markets, including support for approval and launch in tier 2/3 countries.
• Provide key support to the Early Development Team (EDT) leading up to late-stage transition for the cancer vaccine program, ensuring smooth transfer of accountability and successful execution, including transition of neoantigen/antigen-selection and immunogenicity data packages.
• Provide key support to the Medicines Commercialisation Team post-approval in first major markets, ensuring the MDT delivers optimal support to registration and lifecycle management for the cancer vaccine, including combination strategies with checkpoint inhibitors or other immuno-oncology agents.
• Build the Medicine Development Team (MDT) and lead this multi-disciplinary matrix team spanning clinical development, immunology/biomarkers, manufacturing (including personalized/off-the-shelf vaccine platforms), regulatory, safety, medical affairs and commercial; supports differentiated development of team members and own MDT performance in partnership with line managers.
• Establish a compelling vision for the cancer vaccine within GSK's Oncology R&D strategy, accounting for the competitive immuno-oncology and cancer vaccine landscape, and translates GSK's strategy into actionable asset plans across functions.
• Deliver differentiated cancer vaccine medicines of value for patients, stakeholders and markets through an evidence package (including immunogenicity, biomarker and clinical efficacy data) that supports regulatory approval, market access and product lifecycle.
• Deliver the Medicine Development Strategy aligned with GSK's oncology disease strategy, the asset Medicine Vision and the Medicine Profile for the cancer vaccine program.
• Prioritize and maximize the asset's portfolio options, including developing multiple tumor-type indications and combination regimens; makes clear, evidence-based go/no-go/accelerate decisions against the strategy and identifies clear inflection points (e.g., immunogenicity readouts, interim efficacy analyses).
• Embed core processes including cost efficiency, adoption of new vaccine platform technology (e.g., mRNA, neoantigen prediction, personalized vaccine manufacturing), risk identification and management, and compliance with policy.
• Identify and align resources (people and financial), team objectives and strategies behind the vision to ensure successful completion of the cancer vaccine development program.
• Proactively identify unmet medical needs in oncology that could be addressed through new indications or line extensions of the cancer vaccine platform.
• Enhance patient focus by incorporating the voice of the patient into cancer vaccine development plans.
• Promote organizational reputation and drives asset value by engaging and negotiating with internal and external stakeholders, including academic and biotech collaborators in the cancer vaccine space.
• Collaborate with other stakeholders, in particular EDLs and other MDLs, to create strategies that support the organizational vision; shares optimal ways of working and knowledge across the oncology and vaccines portfolios.
• Ensure quality and compliance oversight in line with R&D expectations and project needs; assures the quality of data and science underpinning the cancer vaccine program.
• Serves as the asset's single point of contact and spokesperson to senior management and senior boards (e.g., Chief Scientific Officer, Head of Development, Chief Medical Officer, President of Pharma, Development Review Board and Portfolio Investment Board) and other relevant internal governance committees and external Advisory Committees as needed.
• Increases visibility among external communities (physicians, regulators, patients, payers) to bring cancer vaccine solutions to patients with unmet medical needs, thereby enhancing GSK's reputation.
• Accountable for delivering and managing the asset resourcing plan, and for managing the asset budget to the…